15,000 Shares in Dianthus Therapeutics, Inc. $DNTH Acquired by BIT Capital GmbH

BIT Capital GmbH purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,000 shares of the company’s stock, valued at approximately $618,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of DNTH. Wellington Management Group LLP increased its position in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the period. Braidwell LP purchased a new stake in Dianthus Therapeutics during the third quarter worth approximately $32,859,000. Polar Capital Holdings Plc purchased a new stake in Dianthus Therapeutics during the third quarter worth approximately $29,434,000. Finally, Fairmount Funds Management LLC grew its stake in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after buying an additional 600,000 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Activity

In other news, EVP Ryan Savitz sold 114,367 shares of the company’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Edward Carr sold 43,682 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 349,551 shares of company stock valued at $28,968,156 over the last ninety days. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Trading Down 4.3%

Shares of DNTH stock opened at $80.51 on Friday. The company has a market capitalization of $4.40 billion, a PE ratio of -19.49 and a beta of 1.18. The firm has a fifty day simple moving average of $87.31 and a 200-day simple moving average of $63.70. Dianthus Therapeutics, Inc. has a twelve month low of $16.64 and a twelve month high of $96.50.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DNTH. HC Wainwright boosted their price objective on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Wolfe Research began coverage on shares of Dianthus Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $98.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $117.82.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.